Clinical Trials Browser

Phase 2 × Hepatitis B, Chronic × durvalumab × Clear all

NCT04294498 2025-03-26

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis B, Chronic